Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
62.1M
-
Number of holders
-
60
-
Total shares
-
37.7M
-
Shares change
-
-2.19M
-
Total reported value, excl. options
-
$47.1M
-
Value change
-
-$3.93M
-
Number of buys
-
22
-
Number of sells
-
-43
-
Price
-
$1.25
Significant Holders of Passage BIO, Inc. - Common Stock (PASG) as of Q3 2022
61 filings reported holding PASG - Passage BIO, Inc. - Common Stock as of Q3 2022.
Passage BIO, Inc. - Common Stock (PASG) has 60 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 37.7M shares
of 62.1M outstanding shares and own 60.63% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (8.93M shares), Versant Venture Management, LLC (4.96M shares), Frazier Life Sciences Management, L.P. (3.76M shares), Lynx1 Capital Management LP (2.75M shares), New Leaf Venture Partners, L.L.C. (2.5M shares), VANGUARD GROUP INC (2.02M shares), Deep Track Capital, LP (1.44M shares), BlackRock Inc. (1.34M shares), RENAISSANCE TECHNOLOGIES LLC (1.26M shares), and HIGHLINE CAPITAL MANAGEMENT, L.P. (1.24M shares).
This table shows the top 60 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.